Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder
The DOI matches its Crossref record, with a small difference in title or year; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cariprazine is an atypical antipsychotic currently under investigation as adjunctive therapy in patients with major depressive disorder (MDD) who have inadequate response to standard antidepressant therapy. METHOD: A randomized, double-blind, placebo-controlled, flexible-dose study was conducted from December 2011 to December 2013 in adults who met DSM-IV-TR criteria for MDD and had an inadequate antidepressant response. Eligible patients were randomized to 8-week adjunctive treatment with placebo (n = 269), cariprazine 1-2 mg/d (n = 274), or cariprazine 2-4.5 mg/d (n = 276). The primary efficacy parameter was change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score; P values were adjusted for multiple comparisons. Safety assessments included adverse events, clinical laboratory tests, vital signs, electrocardiograms (ECGs), and suicidality. RESULTS: Compared with placebo, reduction in MADRS total score at week 8 was significantly greater with adjunctive cariprazine 2-4.5 mg/d (least squares mean difference [LSMD] = -2.2; adjusted P = .0114), but not with cariprazine 1-2 mg/d (LSMD = -0.9; adjusted P = .2404). Significant LSMDs for MADRS total score change were detected at all earlier study visits (weeks 2, 4, 6) in the 2- to 4.5-mg/d group and at weeks 2 and 4 in the 1- to 2-mg/d group (all P values < .05). Treatment-emergent adverse events reported in ≥ 10% of patients in either cariprazine dosage group were akathisia (22.3%), insomnia (13.6%), and nausea (12.8%) (all in 2- to 4.5-mg/d group). Mean changes in metabolic parameters, vital signs, and ECG parameters were generally similar between groups. No suicide-related adverse events were reported. DISCUSSION: These results show that adjunctive cariprazine 2-4.5 mg/d was effective and generally well tolerated in adults with MDD who had inadequate responses to standard antidepressants. Further clinical studies to confirm these results are warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01469377.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, cariprazine currently FDA approved for treatment of schizophrenia and bipolar-type I disorder has been studied as an adjunctive agent for MDD showed a significant reduction in MADRS scores at week 8 compared to placebo (Durgam et al., 2016; Earley et al., 2018).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Durgam et al., 2016
Citations
Cites
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
(2007) · PubMed · Cited by 453
Management of nonresponse and intolerance: switching strategies.
D, M. F. M. (2000) · PubMed · Cited by 103
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S.-M., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 92
Wright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
Cited by
Items 101–130 of 130
The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?
Serafini, G., Nasrallah, H. A., & Amore, M. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2059973 · Cited by 2
When an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Aydın, İ. H., Salifu, A., Settle, K., & El‐Mallakh, R. S. (2025) · Annals of Clinical Psychiatry · doi:10.1177/10401237251344096 · Cited by 2
Masand, P. S., Clayton, A. H., Parikh, M., Haile, F., Germain, G., Ripley, S., Ma, S., Laliberté, F., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2587412 · Cited by 1
Pompili, M., Cifrodelli, M., mammoliti, A. V., Formica, F., Iannazzo, R., McIntyre, R. S., & Berardelli, I. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251400653 · Cited by 1
“Durgam et al. (2016b) in an 8-week multi-national, multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with BD disorder experiencing a current major depressive episode confirmed that changes from baseline in laboratory values, vital signs,…”
InfluentialPapakostas, G. I., Masand, P. S., Clayton, A., Maletic, V., Adams, J., Rekeda, L., Singh, M. K., & Kerolous, M. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s561112 · Cited by 1
Khalid, R., Elbashir, G., Hassan, A., & Abdulbagi, M. (2026) · Cureus · doi:10.7759/cureus.109712 · Cited by 1
Le, G. H., Wong, S., Johnson, D. E., Orsini, D. K., Zheng, Y. J., Teopiz, K. M., Dri, C. E., Rosenblat, J. D., & McIntyre, R. S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70344 · Cited by 1
“…flexible-dose study identified significantly greater MADRS improvement with 2.0–4.5 mg/day cariprazine, but not 1–2 mg/ day, relative to placebo, 82 whereas another 6-week fixed-dose study did not detect a statistically significant difference from placebo on the primary MADRS endpoint or the…”
InfluentialCariprazine in the treatment of unipolar depression: Case report
Dodić, S., Dunjić-Kostić, B., Jerotić, S., Lalović, N., Ivković, M., & Pantović-Stefanović, M. (2021) · Engrami · doi:10.5937/engrami43-34089 · Cited by 1
Chue, P. S., & Siraki, A. G. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.029 · Cited by 1
Clinical challenges in the dosing and titration of cariprazine
Miljević, Č., Vuković, P. G., & Munjiza, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1427482 · Cited by 1
Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range
Sattaf, F., Scherf‐Clavel, M., Unterecker, S., Eckert, A. P., Reif, A., & Hahn, M. (2025) · Pharmacopsychiatry · doi:10.1055/a-2511-3744 · Cited by 1
Herman, A. (2017) · uO Research (University of Ottawa) · doi:10.20381/ruor-20993 · Cited by 1
“The second study was conducted on patients that had inadequate response to antidepressants, and found that a dose of 2.0-4.5 mg/day of cariprazine was significantly better than placebo as an augmentation therapy alongside current antidepressant treatment (Durgam et al, 2016).”
BackgroundInfluentialHamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
An “Awakener” Patient Suffering From Treatment-Resistant Depression Following Adjunctive Cariprazine
Bonotis, K. S. (2024) · Cureus · doi:10.7759/cureus.53246
Case reports in psychopharmacology
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4421-1
Prioritizing the Components of Any Decision-Making Model
Goldberg, J. F., & Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009181549.012
Cariprazine: A Complete Solution for Full-Spectrum Bipolar I Disorder?
Bhattacharyya, R. (2022) · D Y Patil Journal of Health Sciences · doi:10.4103/dypj.dypj_61_21
Citrome, L. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as34
Chapter 4. Antipsychotic Drugs
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd04
Giménez‐Palomo, A., Ilzarbe, L., & Vieta, E. (2024) · Psiquiatría Biológica · doi:10.1016/j.psiq.2024.100494
Laha, P., Basavaraju, R., Parameshwaran, S., Dinakaran, D., Malo, P. K., Bhaskarapillai, B., & Kesavan, M. (2024) · Journal of Psychiatry Spectrum · doi:10.4103/jopsys.jopsys_36_24
Drugs under investigation for treatment-resistant depression
Costa, A. P., Machado‐Vieira, R., & Kaster, M. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00034-7 · Cited by 1
Adjunctive strategies for treatment-resistant depression
Thase, M. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00011-6 · Cited by 1
Kidyaeva, A. V., & Nasyrova, R. F. (2025) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2025-3-1196
Die Aktivität des NLRP3-Inflammasoms bei depressiven Patienten in Abhängigkeit von Kindheitstraumata
Lechner, K. (2025) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-40044
Reichelt, L. (2020) · mediaTUM (Technical University of Munich) · Cited by 1
Андреевна, Б. В., Захаров, Д. В., & Mikhailov, V. A. (2026) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2026-2-1096
Cutler, A. J., Lemyre, A., Zhang, Q., Mao, C., Totev, T. I., Gauthier‐Loiselle, M., Wu, Y., Liu, J., Hashim, M., Namjoshi, M., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03630-3
Yardeni, E. H., Kiss, D. J., Sanchez, J., Shavit, K., Kovács, D. S., Egyed, A., Vogt, C. D., Gaitonde, S. A., Glenn, J., Canals, M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef7411
Gao, K., Oruc, E. B., & Koparal, B. (2026) · Medicina · doi:10.3390/medicina62112198
Metadata
- Authors
- Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A.
- Corresponding author
- Durgam, Suresh
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-03-23
- Volume
- 77
- Issue
- 03
- Pages
- 371-378
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2316471784
- Cited by
- 125
- References
- 5
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 17 · 2023: 15 · 2022: 18 · 2021: 7 · 2020: 8 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- cariprazine, major depressive disorder, adjunctive therapy, atypical antipsychotics, antidepressant resistance, akathisia, treatment-emergent adverse events, dose comparison, suicidality, Montgomery-Asberg Depression Rating Scale, tolerability, metabolic parameters, insomnia, nausea, antidepressant efficacy
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Piperazines, Antipsychotic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.